<DOC>
	<DOC>NCT00967018</DOC>
	<brief_summary>Patients that completed any of the trials; CS27 (NCT00738673), CS28 (NCT00831233), CS30 (NCT00833248) or CS31 (NCT00884273) will be given the opportunity to receive monthly doses of degarelix until the drug is launched in their country. Safety parameters such as electrocardiogram (ECG), blood and urine samples and general health state will be studied. Note: patients completing the CS27 trial did not participate in the CS34 trial.</brief_summary>
	<brief_title>A Long Term Safety Study of Degarelix in Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Completed any of the trials; FE 200486 CS27, CS28, CS30 or CS31 Discontinued any of the trials: FE 200486 CS27, CS28, CS30 or CS31</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Safety parameters</keyword>
	<keyword>ECG, blood and urine samples</keyword>
	<keyword>general health state</keyword>
</DOC>